Tom Vanden Berghe obtained his Master's and PhD in Science (Biotechnology) in 1999 and 2005, respectively. Following his doctoral studies, he pursued postdoctoral research at the VIB-UGent Center for Inflammation Research. In 2018, he was appointed as an Assistant Professor at the University of Antwerp and Guest Professor at Ghent University. He was promoted to Associate Professor in 2023 and, through a fast-track procedure, achieved the rank of Professor in 2024.
Professor Vanden Berghe is Head of the Cell Death Signaling (CDS) research group at the University of Antwerp and leads its Ferroptosis Signaling team. Under his leadership, CDS brings together several complementary research teams, each headed by a principal investigator. These include the Epigenetic Signaling team led by Professor Wim Vanden Berghe, the Pyroptosis and Inflammasome Signaling team led by Professor Andy Wullaert, and the Structural Mass Spectrometry team led by Professor Frederik Lermyte. Together, the CDS teams investigate cell death and disease-related processes from molecular, immunological, epigenetic, proteomic and structural perspectives.
Professor Tom Vanden Berghe’s team focuses on the mechanisms, diagnosis and therapeutic modulation of ferroptosis in critical illness, brain injury, and kidney and vascular diseases. It also explores ferroptosis as a strategy for eliminating therapy-resistant cancers. His team has established a comprehensive ferroptosis platform encompassing novel candidate inhibitors and regulatory genes, ferroptosis diagnostics, and ferroptosis-based nanomedicines for cancer treatment.
Full Professor @ UAntwerp
Guest Professor @ UGent
Research coordinator
10% ZAP
Vascular calcification
Postdoctoral fellow
10% ZAP
Kidney disease
Ferroptosis
Epigenetics
Ferroptosis
Chronic interstitial nephritis
Ferroptosis
Chronic kidney disease
Ferroptosis
Ischemia/reperfusion injury
Ferroptosis
Mechanism lipid peroxidation
Endothelial cells
Vascular calcification
Nephrectomy
Regeneration
Precision medicine 2.0 diagnostics
Nanopore episequencing cfDNA
Critical illness
Precision medicin @ICU
Cell death intervention
Ferroptosis
Acute kidney injury
Ferroptosis
Multiple sclerosis
Experimental surgery
Bone histomorphometry
Biochemical analysis
Experimental surgery
Animal follow-up
Bone histomorphometry
Ferroptosis
Anti-cancer therapeutics
Biomedical Laboratory
Spectrometric Analyses
Ferroptosis
Nonalcoholic fatty liver disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Multiple sclerosis
Mechanisms of vascular calcification
Administration
Biochemical analysis
Nephrectomy induced repair
Toxin induced nephropathy
Arterial stiffness in vascular calcification
Metformin
Chronic kidney disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Immunogenicity
Ferroptosis
Multi organ failure
Experimental surgery
Mouse manager
Standard lab analysis
Postdoctoral fellow
Bone histomorphometry
| Title | Cited by |
| Number | Name | Date |
| US9862678, EP3218357 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | 2014-11-14 |
| EP3749645, CN112105601, US20210094909 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | 2018-02-07 |
| WO2015110346, US9919048 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | 2014-01-21 |
| EP4590667, 2026/0109678 | Phenothiazine-based new ferroptosis inhibitors | 2022-09-21 |
| EP24187618 | Novel ferroptosis inhibitors - 2024 016 Ferropcam | 2024-07-10 |
| EP24187620 | Novel ferroptosis inhibitors - 2024 017 Alferopcom | 2024-07-10 |
| EP24187621.8 | Novel ferroptosis inhibitors - 2024 018 Oxaferropcom | 2024-07-10 |
